引用本文
  • 胡薇,施俊义*,盛援,李莉.卡培他滨单药一线治疗Ⅱa期老年乳腺癌的临床研究[J].第二军医大学学报,2009,30(2):187-189    [点击复制]
  • HU Wei,SHI Jun-yi*,SHENG Yuan,LI Li.Clinical observation of capecitabine as first-line monotherapy in elderly patients with Ⅱa breast cancer[J].Acad J Sec Mil Med Univ,2009,30(2):187-189   [点击复制]
【打印本页】 【下载PDF全文】 【HTML】 查看/发表评论下载PDF阅读器关闭

←前一篇|后一篇→

过刊浏览    高级检索

本文已被:浏览 2217次   下载 1478 本文二维码信息
码上扫一扫!
卡培他滨单药一线治疗Ⅱa期老年乳腺癌的临床研究
胡薇,施俊义*,盛援,李莉
0
(第二军医大学长海医院甲乳外科,上海 200433)
摘要:
目的:观察卡培他滨单药一线治疗Ⅱa期老年乳腺癌的临床疗效和不良反应。方法:2002年6月至2005年6月本院收治的71例Ⅱa期老年乳腺癌,患者术后分别行卡培他滨单药口服化疗(X组)及CEF方案化疗(CEF组)。结果:X组3年和5年总生存率分别为97.06%、94.12%,复发及转移率为5.88%,均与CEF组患者无明显差异(P>0.05)。X组具有口服给药的优势,不良反应以手足综合征为主,发生率82.35%,均可耐受,其胃肠道反应以及骨髓抑制程度等均显著低于CEF组(P<0.01),未有因不良反应减量、中断或放弃化疗者,且无明显化疗恐惧感。结论:对于Ⅱa期老年乳腺癌患者术后采用卡培他滨单药口服化疗疗效可靠,给药方便,不良反应极小,患者对治疗的耐受及依从性佳。
关键词:  乳腺肿瘤  药物疗法  卡培他滨  老年人
DOI:10.3724/SP.J.1008.2009.0187
投稿时间:2008-09-13修订日期:2008-12-09
基金项目:
Clinical observation of capecitabine as first-line monotherapy in elderly patients with Ⅱa breast cancer
HU Wei,SHI Jun-yi*,SHENG Yuan,LI Li
(Department of Thyroid and Breast Surgery,Changhai Hospital,Second Military Medical University,Shanghai 200433,China)
Abstract:
Objective:To observe the clinical effect and adverse reaction of capecitabine as first-line monotherapy in elderly patients with stage Ⅱa breast cancer.Methods: From June 2002 to June 2005,71 elderly patients with stage Ⅱa breast cancer received chemotherapy(different scheme: capecitabine group and CEF group) after operation.The efficacies and adverse reactions were evaluated and compared between the two groups.Results: The 3-year and 5-year survival rates of patients in capecitabine group were 97.06% and 94.12%,respectively; the relapse rate was 5.88%; all were comparable to those of CEF group. One of the advantages of capecitabine was its oral administration. The adverse effect of capecitabine was mainly hand-foot syndrome,with an incidence of 82.35%,but was tolerable. The gastrointestinal reaction and bone marrow repression in capecitabine group were significantly lower than those in the CEF group(P<0.01). There was no giving up of treatment due to adverse reactions or fear of chemotherapy in our group. Conclusion: Capecitabine is effective and safe in the treatment of elderly patients with stage Ⅱa breast cancer; it is easy to take,with less adverse effects and better patient compliance.
Key words:  breast neoplasms  drug therapy  capecitabine  aged